News and Reports
-
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis
28 May 2024Download -
Swixx BioPharma Expands to Latin America Through a Strategic Acquisition and Combination with Biopas
22 May 2024Download -
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
9 May 2024Download -
Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis
2 May 2024Download -
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
15 April 2024Download -
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
2 April 2024Download -
eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient
21 March 2024Download -
Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients
7 March 2024Download -
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
6 March 2024Download -
Shape Memory Medical Completes $38 Million in Financing to Advance Endovascular Embolization
4 March 2024Download -
FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
1 March 2024Download -
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
15 February 2024Download -
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
14 February 2024Download -
Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX10
6 February 2024Download -
Cathay Biotech Inc. and 3P.COM Co. Limited Signed Joint Venture Agreement to Propel Thermoplastic Bio-Based Polyamide Composites Innovation
2 February 2024Download -
Cathay Biotech’s Progress Report in Bio-based High Temperature Polyamides (PPA) and Composite Technologies
2 February 2024Download -
ArriVent Announces Pricing of Upsized Initial Public Offering
25 January 2024Download -
eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
19 January 2024Download -
Upstream Bio Announces Dosing of First Patients in a Phase 2 Clinical Trial of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
3 January 2024Download -
Shape Memory Medical Announces Sublicense of Intellectual Property
11 December 2023Download -
Synthetic Biology’s Great Attack - Dr. Xiucai Liu, Chairman of Cathay Biotech, discussing the status and future of the synthetic biology industry
30 November 2023Download -
Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer
30 October 2023Download -
Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2
24 October 2023Download -
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
19 October 2023Download -
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
17 October 2023Download